Low Risk for Hepatitis C Virus Reinfection in Patients with Opioid Use Disorder

Among injection drug users receiving opioid agonist therapy, the HCV reinfection rate following antiviral therapy was only 1.22 cases per 100 person-years.

Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is effective in achieving sustained viral responses. However, the risk for reinfection associated with such treatment among people who inject drugs is unclear.

To address this issue, investigators conducted an extension of the PREVAIL study (NCT01857245), a randomized controlled trial of three models of HCV care among 150 injection drug users receiving opioid agonist therapy. Of the 141 participants who achieved a sustained virologic response by the end of the PREVAIL study, 114 were recruited for the extension study.

At a mean follow-up of 20.5 months, three participants were reinfected with HCV; two had reinfection, confirmed by next-generation sequencing, between 12 and …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Low Risk for Hepatitis C Virus Reinfection in Patients with Opioid Use Disorder

Topics

Reviewing Author